M. Raderer
Department of Internal Medicine I
University of Vienna
Austria
Name/email consistency: high
- Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease. Raderer, M., Püspök, A., Stummvoll, G., Längle, F., Chott, A. Scand. J. Gastroenterol. (2003)
- Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?. Raderer, M., Chott, A., Drach, J., Montalban, C., Dragosics, B., Jäger, U., Püspök, A., Osterreicher, C., Zielinski, C.C. Ann. Oncol. (2002)
- Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Raderer, M., Kurtaran, A., Scheithauer, W., Fiebiger, W., Weinlaender, G., Oberhuber, G. Oncology (2001)
- Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Raderer, M., Osterreicher, C., Machold, K., Formanek, M., Fiebiger, W., Penz, M., Dragosics, B., Chott, A. Ann. Oncol. (2001)
- Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century. Raderer, M., Isaacson, P.G. Expert. Rev. Anticancer. Ther (2001)
- Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type. Raderer, M., Valencak, J., Pfeffel, F., Drach, J., Pangerl, T., Kurtaran, A., Hejna, M., Vorbeck, F., Chott, A., Virgolini, I. J. Natl. Cancer Inst. (1999)
- Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo. Raderer, M., Pangerl, T., Leimer, M., Valencak, J., Kurtaran, A., Hamilton, G., Scheithauer, W., Virgolini, I. J. Natl. Cancer Inst. (1998)
